LSNE Successfully Completes MHRA Inspection - - BioPharm International

ADVERTISEMENT

LSNE Successfully Completes MHRA Inspection



The CMO Lyophilization Services of New England (LSNE) reports that its manufacturing facility in Bedford, New Hampshire has received a Certificate of GMP Compliance from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture asepticlyophilized drug products for use in the European Union. LSNE underwent an initial inspection in May 2013 and was found to be compliant with EU GMP, with no critical or major findings. After completion of an audit and registration, LSNE was issued a certificate ofGMP compliance of a Pharmaceutical Manufacturer from the MHRA. The Bedford facility is now certified for the manufacture of sterile lyophilized drug products to be marketed in the EU.

Source: LSNE

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Author Guidelines

Click here